Compare McKesson Corporation (MCK) vs NetEase Inc (NTES) Price & Performance

McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.

The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.

NetEase (NTES) trades at $120.61, up 1.29% with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $112.63B revenue and 27.88% net margin in 2025, though recent quarterly earnings show volatility with two misses in the last three quarters. Analyst consensus remains strongly bullish with 82% buy ratings and a $168 price target representing 39% upside potential.

The investment case balances strong profitability and cash generation against earnings volatility and competitive pressures. Key opportunities include consistent revenue growth and attractive valuation multiples, while risks center on gaming market competition and China regulatory environment. The stock presents value for long-term investors given the significant discount to analyst targets.